Home » Stocks » RXRX

Recursion Pharmaceuticals, Inc. (RXRX)

Stock Price: $28.00 USD -3.30 (-10.54%)
Updated Apr 19, 2021 4:00 PM EDT - Market closed
Market Cap 4.54B
Revenue (ttm) 3.96M
Net Income (ttm) -87.01M
Shares Out 162.16M
EPS (ttm) -0.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $28.00
Previous Close $31.30
Change ($) -3.30
Change (%) -10.54%
Day's Open 28.50
Day's Range 25.21 - 29.05
Day's Volume 989,960
52-Week Range 25.17 - 33.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Recursion Pharmaceuticals, Inc. ("Recursion" or "we") today announced the pricing of its initial public offering of its Class A common stock at...

4 days ago - PRNewswire

After initially indicating it intended to raise $100 million in its Nasdaq debut, the Salt Lake City-based company will now look at bringing in approximately $306 million.

1 week ago - BioSpace

Recursion Pharmaceuticals, a Phase 2-ready biotech using machine learning to develop therapies for various indications, filed on Monday with the SEC to raise up to $100 million in an initial public offe...

4 weeks ago - NASDAQ

Recursion Pharmaceuticals, Inc. has filed to go public with an IPO on the NASDAQ.

4 weeks ago - SEC

About RXRX

Recursion Pharmaceuticals is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. In mid-2020 we began transitioning from ‘brute-force search’ approaches, where we physically test every combination of disease model and drug candidate in our library using our automated wet-lab infrastructure, to a more efficient and even more powerful ... [Read more...]

Industry
Biotechnology
IPO Date
Apr 16, 2021
CEO
Christopher Gibson
Employees
331
Stock Exchange
NASDAQ
Ticker Symbol
RXRX
Full Company Profile

Financial Performance

In 2020, RXRX's revenue was $3.96 million, an increase of 70.85% compared to the previous year's $2.32 million. Losses were -$87.01 million, 40.6% more than in 2019.

Financial Statements